Phase 2 FIT Clinical Trials
5 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–5 of 5 trials
Recruiting
Phase 2
Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study
RituximabMCLBTKi+2 more
M.D. Anderson Cancer Center30 enrolled1 locationNCT07257055
Recruiting
Phase 1Phase 2
Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML
Acute Myeloid Leukemia (AML)CEBPA MutationUnfit, New-diagnosis AML
The First Affiliated Hospital of Soochow University29 enrolled1 locationNCT07451912
Recruiting
Phase 2
Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML
Acute Myeloid LeukemiaIntermediate Risk Acute Myeloid LeukemiaFLT3 Internal Tandem Duplication Positive+1 more
First Affiliated Hospital of Zhejiang University25 enrolled1 locationNCT07259707
Recruiting
Phase 2
Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML
Newly Diagnosed Acute Myeloid Leukemia (AML)Intensive Chemotherapy UnfitAge ≥60
First Affiliated Hospital of Zhejiang University25 enrolled5 locationsNCT07172204
Completed
Phase 2
A multi-centre phase II trial of early treatment intensification with R-ICE (rituximab – ifosfamide, carboplatin, etoposide) chemotherapy followed by BEAM ( BCNU(BCNU is Carmustine), etoposide, ara-C (ara-C is Cytarabine), melphalan) high dose chemotherapy and autologous stem cell transplantation for patients with poor prognosis diffuse large B-cell lymphoma
Patients with CD20+ diffuse large B cell lymphoma (DLBCL) with low intermediate, high intermediate, or high risk disease or low risk disease with bulky tumour (> 7.5 cm) who are considered fit and eligible for high dose chemotherapy (HDCT) with Z-BEAM ( Zevalin - BEAM ( BCNU(BCNU is Carmustine), etoposide, ara-C (ara-C is Cytarabine), melphalan) and autologous stem cell transplantation (ASCT).
Australasian Leukaemia and Lymphoma Group (ALLG)162 enrolled1 locationACTRN12609001077257